Inventor · disambiguated record
Rahul Palchaudhuri
Also filed as: PALCHAUDHURI RAHUL
19 granted patents·16 pending applications·42 citations·filing 2007–2024
92Inventor score
Files withMAGENTA THERAPEUTICS INC16HARVARD COLLEGE6UNIV ILLINOIS5CRISPR THERAPEUTICS AG2HEIDELBERG PHARMA RES GMBH2
Top patents by PatentIndex Score
35 records- 0192US10899843B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 26, 2021·8 cites·38 claims
- 0292US10280225B2Compositions and methods for non-myeloablative conditioningHARVARD COLLEGE·Filed 2016·Granted May 7, 2019·10 cites·25 claims
- 0391US10882915B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·9 cites·27 claims
- 0489US11572411B2Anti-CD117 antibodies and conjugatesMAGENTA THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·2 cites·14 claims
- 0588US10570207B2Compositions and methods for non-myeloablative conditioningHARVARD COLLEGE·Filed 2018·Granted Feb 25, 2020·5 cites·15 claims
- 0685US12251448B2Compositions and methods for the depletion of CD5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Mar 18, 2025·1 cites·13 claims
- 0784US11958908B2Compositions and methods for the depletion of CD117+ cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Apr 16, 2024·1 cites·26 claims
- 0882US9611266B2Compounds and anti-tumor NQO1 substratesUNIV ILLINOIS·Filed 2016·Granted Apr 4, 2017·3 cites·20 claims
- 0979US10434185B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·1 cites·29 claims
- 1078US2024360238A1Compositions and methods for the depletion of cd117+ cellsCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1177US2025082767A1Compositions and methods for the depletion of cd5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1276US12209135B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2024·Granted Jan 28, 2025·0 cites·22 claims
- 1375US12152080B2Compositions and methods for non-myeloablative conditioningHARVARD COLLEGE·Filed 2020·Granted Nov 26, 2024·0 cites·49 claims
- 1475US10906980B2Compositions and methods for non-myeloablative conditioningHARVARD COLLEGE·Filed 2019·Granted Feb 2, 2021·0 cites·30 claims
- 1575US10576161B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·1 cites·24 claims
- 1669US9233960B2Compounds and anti-tumor NQO1 substratesHERGENROTHER PAUL J·Filed 2012·Granted Jan 12, 2016·1 cites·20 claims
- 1766US2024075157A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1860US2020276326A1Compositions and methods for the depletion of cd5+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1959US10285986B2Compounds and anti-tumor NQO1 substratesUNIV ILLINOIS·Filed 2018·Granted May 14, 2019·0 cites·25 claims
- 2059US2020289664A1Compositions and methods for the depletion of cd137+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2156US9925180B2Compounds and anti-tumor NQO1 substratesUNIV ILLINOIS·Filed 2017·Granted Mar 27, 2018·0 cites·23 claims
- 2256US9682060B2Small molecules that induce intrinsic pathway apoptosisUNIV ILLINOIS·Filed 2016·Granted Jun 20, 2017·0 cites·20 claims
- 2356US2022177578A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2456US2022177575A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2556US2022175946A1Conditioning methods for gene therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2654US2020376135A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2754US2023183344A1T-cell bispecific binding proteinsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2853US12291576B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2021·Granted May 6, 2025·0 cites·26 claims
- 2951US2022175951A1Anti-CD45 Antibody Drug Conjugates and Uses ThereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3049US2016122405A1Homeodomain fusion proteins and uses thereofHARVARD COLLEGE·Filed 2014·Application pending·0 cites
- 3147US7709465B2Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancersUNIV ILLINOIS·Filed 2007·Granted May 4, 2010·0 cites·47 claims
- 3247US2021379195A1Methods for allogeneic hematopoietic stem cell transplantationMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3346US2020255523A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3445US2020368363A1Compositions and methods for the depletion of cd2+ cellsMAGENTA THEERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3542US2020040093A1Compositions and methods for non-myeloablative conditioningHARVARD COLLEGE·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rahul Palchaudhuri files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →